The U.S. Food and Drug Administration has approved Vetoquinol USA’s Imoxi Topical Solution for Cats, a generic equivalent of Bayer’s Advantage Multi antiparasitic.
Imoxi Topical Solution for Cats (imidacloprid and moxidectin) is formulated to prevent heartwormsand treat fleas, ear mites and intestinal parasites.
The prescription drug’s approval came five months after the FDA authorized Imoxi Topical Solution for Dogs, which contains the same active ingredients.
Administered monthly, the feline version will be sold in three dosages based on a cat’s weight: 2 to 5 pounds, 5.1 to 9 pounds and 9.1 pounds or more.
Bayer Animal Health earned FDA approval of Advantage Multi for Cats (imidacloprid and moxidectin) in 2007.